Patient info Open main menu

Xalatan 50 micrograms / ml eye drops solution – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
50 micrograms / ml
Other strengths and forms:
Contains active substance:
Similar medicines:

Patient leaflet - Xalatan 50 micrograms / ml eye drops solution

1. What Xalatan is and what it is used for

Xalatan belongs to a group of medicines known as prostaglandin analogues. It works by increasing the natural outflow of fluid from inside the eye into the bloodstream.

Xalatan is used to treat conditions known as open angle glaucoma and ocular hypertension in adults. Both of these conditions are linked with an increase in the pressure within your eye, eventually affecting your eye sight.

Xalatan is also used to treat increased eye pressure and glaucoma in all ages of children and babies.

2. What you need to know before you use Xalatan

Xalatan can be used in adult men and women (including the elderly) and in children from birth to 18 years of age. Xalatan has not been investigated in prematurely born infants (less than 36 weeks gestation).

Do not use Xalatan:

  • If you are allergic (hypersensitive) to latanoprost or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor or the doctor treating your child or pharmacist before using Xalatan or before you give this to your child if you think any of the following apply to you or your child:

  • If you or your child are about to have or have had eye surgery (including cataract surgery) • If you or your child suffer from eye problems (such as eye pain, irritation or inflammation, blurred vision)
  • If you or your child suffers from dry eyes
  • If you or your child have severe asthma or the asthma is not well controlled • If you or your child wear contact lenses. You can still use Xalatan, but follow the instruction for contact lens wearers in Section 3
  • If you have suffered or are currently suffering from a viral infection of the eye caused by the herpes simplex virus (HSV)

Other medicines and Xalatan

Xalatan may interact with other medicines. Please tell your doctor, the doctor treating your child or pharmacist if you or your child are using or have used any other medicines including those medicines (or eye drops) obtained without a prescription. In particular, speak to your doctor or pharmacist if you know that you are using prostaglandins, prostaglandin analogues or prostaglandin derivatives.

Pregnancy and breast-feeding

You should not use Xalatan if you are pregnant or breast-feeding unless your doctor considers it necessary. If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine.

Driving and using machines

When you use Xalatan you might have blurred vision, for a short time. If this happens to you, do not drive or use any tools or machines until your vision becomes clear again.

Xalatan contains Benzalkonium chloride and phosphate buffers

This medicine contains 0.2 mg/mL of benzalkonium chloride.

Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards.

Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.

This medicine contains 6.3 mg/mL phosphates which is equivalent to 0.2 mg/drop.

If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.

3. How to use Xalatan

Always use Xalatan exactly as your doctor or the doctor treating your child has told you. You should check with your doctor or the doctor treating your child or pharmacist if you are not sure.

The recommended dosage for adults (including the elderly) and children is one drop once a day in the affected eye(s). The best time to do this is in the evening.

Do not use Xalatan more than once a day, because the effectiveness of the treatment can be reduced if you administer it more often.

Use Xalatan as instructed by your doctor or by the doctor treating your child until they tell you to stop.

Contact lens wearers

If you or your child wear contact lenses, they should be removed before using Xalatan. After using Xalatan you should wait 15 minutes before putting the contact lenses back into the eyes.

Instructions for use

  1. 1. Wash your hands and sit or stand comfortably.
  2. 2. Twist off the outer cap (which can be thrown away).
  3. 3.

    Unscrew the protective inner cap. The protective cap should be

    retained.

  4. 4.

    Use your finger to gently pull down the lower eyelid of your

    affected eye.

  5. 5. Place the tip of the bottle close to, but not touching your eye.
  6. 6.

    Squeeze the bottle gently so that only one drop goes into your

    eye, then release the lower eyelid.

  7. 7.

    Press a finger against the corner of the affected eye by the nose.

    Hold for 1 minute whilst keeping the eye closed.

  8. 8.

    Repeat in your other eye if your doctor has told you to do this. 9. Put the protective inner cap back on the bottle.

    PAA243752

    0200

2 of 2

Date: Time:

DescriptionXalatan_0.05mg _1ml_2.5
LeafletSite Barcode/ DataMatrixITF - 02004No. of colours1Page Count
3958001Viatris SAP No.400567340
3193380122386455/0103
39580012
MA No.United Kingdomwith
Supplier SAP No.N/A
New Supplier CodePAA2437523D Render IDN/AMain FontHelvetica Neue LT Pro7 pt
PAA211513105 x 432 mm7 pt

16:30 09-NOV-2025

Mix-up codes
PL 46302/0327
N/A
GTIN/PCN/A

If you use Xalatan with other eye drops

Wait at least 5 minutes between using Xalatan and taking other eye drops

If you use more Xalatan than you should

If you put too many drops into the eye, it may lead to some minor

irritation in the eye and the eyes may water and turn red. This

should pass, but if you are worried contact your doctor or the

doctor treating your child for advice.

Contact your doctor as soon as possible if you or your child

swallows Xalatan accidentally.

If you forget to use Xalatan

Carry on with the usual dosage at the usual time. Do not take

a double dose to make up for the dose you have forgotten. If you are unsure about anything talk to your doctor or pharmacist.

If you stop using Xalatan

You should speak to your doctor or the doctor treating your child if you want to stop taking Xalatan.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following are known side effects of using Xalatan:

Very common (may affect more than 1 in 10 people):

  • A gradual change in your eye colour by increasing the amount of brown pigment in the coloured part of the eye known as the iris. If you have mixed-colour eyes (blue-brown, grey-brown, yellow-brown or green-brown) you are more likely to see this change than if you have eyes of one colour (blue, grey, green or brown eyes). Any changes in your eye colour may take years to develop although it is normally seen within 8 months of treatment. The colour change may be permanent and may be more noticeable if you use Xalatan in only one eye. There appears to be no problems associated with the change in eye colour. The eye colour change does not continue after Xalatan treatment is stopped.
  • Redness of the eye.
  • Eye irritation (a feeling of burning, grittiness, itching, stinging or the sensation of a foreign body in the eye). If you experience eye irritation severe enough to make your eyes water excessively, or make you consider stopping this medicine, talk to your doctor, pharmacist or nurse promptly (within a week). You may need your treatment to be reviewed to ensure you keep receiving appropriate treatment for your condition. • A gradual change to eyelashes of the treated eye and the fine hairs around the treated eye, seen mostly in people of Japanese origin. These changes involve an increase of the colour (darkening), length, thickness and number of your eye lashes.

Common (may affect up to 1 in 10 people):

  • Irritation or disruption to the surface of the eye, eyelid inflammation (blepharitis), eye pain, light sensitivity (photophobia), conjunctivitis.

Uncommon (may affect up to 1 in 100 people):

  • Eyelid swelling, dryness of the eye, inflammation or irritation of the surface of the eye

    (keratitis), blurred vision, inflammation of the coloured part of the eye (uveitis), swelling of the retina (macular oedema).

  • Skin rash.
  • Chest pain (angina), awareness of heart rhythm (palpitations).
  • Asthma, shortness of breath (dyspnoea).
  • Chest pain.
  • Headache, dizziness.
  • Muscle pain, joint pain.
  • Nausea, vomiting.

Rare (may affect up to 1 in 1000 people):

  • Inflammation of the iris (iritis), symptoms of swelling or scratching/damage to the surface of the eye, swelling around the eye (periorbital oedema), misdirected eyelashes or an extra row of eyelashes, scarring of the surface of the eye, fluid filled area within the coloured part of the eye (iris cyst).
  • Skin reactions on the eyelids, darkening of the skin of the eyelids. • Worsening of asthma.
  • Severe itching of the skin.
  • Developing a viral infection of the eye caused by the herpes simplex virus (HSV).

Very rare (may affect up to 1 in 10,000 people):

  • Worsening of angina in patients who also have heart disease, sunken eye appearance (eye sulcus deepening).

Side effects seen more often in children compared to adults are runny itchy nose and fever.

In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Xalatan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle. The expiry date refers to the last day of that month.

Store the unopened bottle at room temperature (Do not store above 25°C), protected from light.

After opening the bottle store it at room temperature (Do not store above 25°C) and use within 4 weeks of opening. When you are not using Xalatan, keep the bottle in the outer carton, in order to protect it from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Content of the pack and other information

What Xalatan contains

The active substance is 50 micrograms/mL latanoprost.

The other ingredients are: benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate monohydrate (E339i) and disodium phosphate anhydrous (E339ii) dissolved in water for injections.

What Xalatan looks like and contents of the pack

Xalatan Eye drops is a clear, colourless liquid.

Xalatan is available in pack sizes of 1, 3 or 6 bottles. Not all pack sizes may be marketed. Each bottle contains 2.5 mL of Xalatan Eye drops.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Viatris Products Limited,

Station Close,

Potters Bar,

EN6 1TL,

United Kingdom.

Manufacturer: Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium.

This leaflet was last revised in: 12/2025

This medicinal product is authorised in the Member States of the EEA under the following names:

Xalatan: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, United Kingdom.

PAA243752 3958001

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 46302/0327

Last revision stated in the text: December 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Xalatan 50 micrograms / ml eye drops solution

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Latanoprost
Strength 50 micrograms / ml
Pharmaceutical form Eye drops
The solution is a clear colourless liquid.
How is it taken Ocular
Excipients Sodium chloride, Benzalkonium chloride, Sodium dihydrogen phosphate monohydrate (E339i), Disodium phosphate anhydrous (E339ii), Water for injections
Pack sizes 2.5 ml
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life Before first opening: 2 years
After first opening of container: 4 weeks
Storage Do not store above 25°C
After first opening: Use within 4 weeks (see section 6.3).
Keep the bottle in the outer carton in order to protect from light.
Drug group (ATC) Ophthalmologicals; Antiglaucoma preparations and miotics, prostaglandin analogues
  1. S Sensory organ drugs
    1. S01 Ophthalmologicals
      1. S01E Antiglaucoma preparations and miotics
        1. S01EE Prostaglandin analogues, antiglaucoma drugs and miotics
          1. S01EE01 latanoprost
Marketing authorisation PL 46302/0327 (first authorised 16 December 1996)
Marketing authorisation holder Viatris Products Limited
Codes GTIN 1210001140806 · BNF 11060000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.